Literature DB >> 15288988

Orbital irradiation for Graves' ophthalmopathy: Is it safe? A long-term follow-up study.

Iris M M J Wakelkamp1, Hendra Tan, Peerooz Saeed, Reinier O Schlingemann, Frank D Verbraak, Leo E C M Blank, Mark F Prummel, Wilmar M Wiersinga.   

Abstract

PURPOSE: We evaluated the frequency of long-term complications of orbital irradiation (radiation-induced tumors, cataract, and retinopathy) in comparison with glucocorticoids.
DESIGN: We conducted a follow-up study in a cohort of 245 Graves' ophthalmopathy patients who had been treated with retrobulbar irradiation (20 Gy in 2 weeks) and/or oral glucocorticoids between 1982 and 1993 in our institution. Irradiated patients were compared with nonirradiated patients.
METHODS: Data on mortality and cause of death were obtained. Living patients were invited to participate in a follow-up study. Possible retinopathy was assessed in a masked fashion and defined as the presence of > or =1 hemorrhages and/or microaneurysms on red-free retina photographs. If >5 lesions were present, patients were categorized as suffering from definite retinopathy. Cataract was assessed using the Lens Opacity Classification System II score. MAIN OUTCOME MEASURES: Mortality, prevalence of retinopathy, prevalence of cataract, and type of cataract.
RESULTS: Thirty-seven of the 245 patients had died, none of them from an intracranial tumor. Mortality was similar in the irradiated (27/159 [17%]) and nonirradiated patients (10/86 [12%]; P = 0.264). One hundred fifty-seven of the 208 living patients (75%) consented to participate in a follow-up ophthalmologic investigation; the mean follow-up time (+/- standard deviation) was 11+/-3 years. Possible retinopathy was present in 15% of patients, 22 of the irradiated and 1 of the nonirradiated patients (P = 0.002). In 5 patients (all had been irradiated), definite retinopathy (i.e., >5 retinal lesions) was present. Of these, 3 had diabetes mellitus, and 1 had hypertension. Diabetes was associated with both possible (P = 0.029) and definite (P = 0.005) retinopathy, with a relative risk of 21 (95% confidence interval, 3-179). The prevalence and severity of cataract were similar in the radiotherapy group (29%) and the glucocorticoid group (34%); it should be noted that 88 of 104 of the irradiated patients were also treated with oral glucocorticoids.
CONCLUSION: The data suggest that orbital irradiation for Graves' ophthalmopathy is a safe treatment modality, except possibly for diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15288988     DOI: 10.1016/j.ophtha.2003.12.054

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  27 in total

1.  Thyroid-associated orbitopathy.

Authors:  Adel H Alsuhaibani; Jeffrey A Nerad
Journal:  Semin Plast Surg       Date:  2007-02       Impact factor: 2.314

2.  Efficacy of combined orbital radiation and systemic steroids in the management of Graves' orbitopathy.

Authors:  Ji Won Kim; Sun Hyup Han; Byeong Jae Son; Tyler Hyungtaek Rim; Ki Chang Keum; Jin Sook Yoon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-15       Impact factor: 3.117

Review 3.  An update on medical management of Graves' ophthalmopathy.

Authors:  L Bartalena; C Marcocci; M L Tanda; E Piantanida; A Lai; M Marinò; A Pinchera
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

Review 4.  Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

5.  [Drug therapy and radiotherapy in Graves' orbitopathy].

Authors:  F Beisse; W A Lagrèze; M Schmucker
Journal:  Ophthalmologe       Date:  2011-05       Impact factor: 1.059

6.  Improvement of the MRI and clinical features of Asian Graves' ophthalmopathy by radiation therapy with steroids.

Authors:  Zichang Ma; Hiroshi Ozaki; Yojiro Ishikawa; Keiichi Jingu
Journal:  Jpn J Radiol       Date:  2019-06-14       Impact factor: 2.374

Review 7.  The evaluation and treatment of graves ophthalmopathy.

Authors:  Marius N Stan; James A Garrity; Rebecca S Bahn
Journal:  Med Clin North Am       Date:  2012-02-22       Impact factor: 5.456

8.  Secondary malignancy following radiotherapy for thyroid eye disease.

Authors:  Christopher C Gillis; Eun Hae Chang; Khalid Al-Kharazi; Tom Pickles
Journal:  Rep Pract Oncol Radiother       Date:  2016-02-08

9.  Radiotherapy in the treatment of Graves ophthalmopathy-to do it or not?

Authors:  Aneta Zygulska
Journal:  J Ocul Biol Dis Infor       Date:  2009-10-06

10.  Update on thyroid eye disease and management.

Authors:  Erick D Bothun; Ryan A Scheurer; Andrew R Harrison; Michael S Lee
Journal:  Clin Ophthalmol       Date:  2009-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.